Focused On-demand Library for RNA-binding protein NOB1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9ULX3

UPID:

NOB1_HUMAN

Alternative names:

Phosphorylation regulatory protein HP-10; Protein ART-4

Alternative UPACC:

Q9ULX3; Q7L6B7; Q7M4M4; Q7Z4B5; Q9NWB0

Background:

RNA-binding protein NOB1, also known as Phosphorylation regulatory protein HP-10 and Protein ART-4, plays a crucial role in cellular processes. It is involved in mRNA degradation and is essential for the processing of 20S pre-rRNA precursor, facilitating the biogenesis of 40S ribosomal subunits. This protein's function underscores its importance in the maintenance and efficiency of the ribosome, the cell's protein factory.

Therapeutic significance:

Understanding the role of RNA-binding protein NOB1 could open doors to potential therapeutic strategies. Its pivotal role in ribosomal biogenesis and mRNA degradation pathways highlights its potential as a target for interventions in diseases where these processes are dysregulated.